Form 10-Q Sorrento Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Sorrento Therapeutics (SRNE) Posts Q3 GAAP Loss of 27c/Share
November 4, 2014 2:54 PM ESTSorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.27), which may not compare with the analyst estimate of ($0.32). Revenue for the quarter came in at $1.28 million versus the consensus estimate of $760 thousand.
For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.
... More